| Literature DB >> 29253005 |
Shouyi Li1, Huiqiang Jiang1, Ningke Du2.
Abstract
Osteoporosis has been reported to be at least partially developed in response to functional polymorphisms of the osteoprotegerin (OPG). However, conflicting results have been found. This meta-analysis aimed to provide an assessment of the relationship between the risk for developing osteoporosis and OPG T950C polymorphism in the Chinese population. Studies to be analyzed were identified with the literature search in PubMed, Embase, Web of Science, the Cochrane Library, and the Chinese National Knowledge Infrastructure during May 2017. Seven case-control studies that included a total of 1850 osteoporosis cases and 3074 controls were assessed in this meta-analysis. Overall, no significant associations could be detected between OPG T950C polymorphism and osteoporosis when all included studies were pooled into this meta-analysis. In a subgroup analyses, OPG T950C polymorphism was significantly associated with the osteoporosis risk in South China (CC+TC vs. TT: OR = 1.34, 95% CI = 1.17-1.54; CC vs. TC+TT: OR = 0.79, 95% CI = 0.69-0.95) and for studies that included postmenopausal osteoporosis (CC vs. TC+TT: OR = 0.78, 95% CI = 0.64-0.94) or hospital-based controls (CC vs. TC+TT: OR = 0.81, 95% CI = 0.68-0.96). In conclusion, the results of this meta-analysis suggest that OPG T950C polymorphism might be associated with an increased osteoporosis risk in the Chinese population.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29253005 PMCID: PMC5734735 DOI: 10.1371/journal.pone.0189825
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Literature search flow diagram.
Association of the OPG T950C polymorphism on the propensity to develop osteoporosis.
| Analysis model | n | ORr(95%CI) | ORf(95%CI) | Ph | |
|---|---|---|---|---|---|
| C vs. T | Total analysis | 7 | 1.08 (0.92–1.26) | 1.08 (0.99–1.17) | 0.095 |
| Hospital-based | 6 | 1.03 (0.90–1.19) | 1.06 (0.97–1.15) | 0.228 | |
| South China | 4 | 1.09 (0.99–1.19) | 1.09 (0.99–1.19) | 0.561 | |
| North China | 3 | 1.00 (0.63–1.60) | 1.04 (0.85–1.27) | 0.014 | |
| Postmenopausal women | 5 | 1.04 (0.87–1.25) | 1.07 (0.97–1.17) | 0.168 | |
| CC vs. TT | Total analysis | 7 | 1.08 (0.77–1.51) | 0.99 (0.82–1.19) | 0.087 |
| Hospital-based | 6 | 0.94 (0.74–1.20) | 0.94 (0.77–1.14) | 0.333 | |
| South China | 4 | 0.96 (0.78–1.19) | 0.97 (0.78–1.19) | 0.412 | |
| North China | 3 | 1.00 (0.41–2.45) | 1.08 (0.73–1.59) | 0.019 | |
| Postmenopausal women | 5 | 0.96 (0.66–1.38) | 0.93 (0.76–1.15) | 0.220 | |
| CC vs. TC+TT | Total analysis | 7 | 1.08 (0.75–1.56) | 0.87 (0.73–1.02) | 0.011 |
| Hospital-based | 6 | 0.89 (0.68–1.16) | 0.81 (0.68–0.96) | 0.197 | |
| South China | 4 | 0.98 (0.68–1.53) | 0.79 (0.69–0.95) | 0.098 | |
| North China | 3 | 1.16 (0.59–2.29) | 1.15 (0.83–1.60) | 0.038 | |
| Postmenopausal women | 5 | 0.90 (0.62–1.29) | 0.78 (0.64–0.94) | 0.165 | |
| CC+TC vs. TT | Total analysis | 7 | 1.11 (0.85–1.47) | 1.27 (1.12–1.44) | 0.026 |
| Hospital-based | 6 | 1.07 (0.78–1.46) | 1.27 (1.11–1.44) | 0.015 | |
| South China | 4 | 1.24 (0.93–1.66) | 1.34 (1.17–1.54) | 0.133 | |
| North China | 3 | 0.90 (0.50–1.59) | 0.96 (0.70–1.31) | 0.075 | |
| Postmenopausal women | 5 | 1.08 (0.74–1.59) | 1.30 (1.14–1.49) | 0.015 | |
ORr: Odd ratio for random-effects model; ORf: Odd ratio for fixed-effects model; Ph: P value for heterogeneity test; South China including Chongqing, Guangdong, Chongqing and Shanghai; North China including Heilongjiang, Beijing, and Shandong.
Fig 2Forest plot for the association between OPG T950C polymorphism and the risk to develop osteoporosis under the allele fixed-effect model.